ClinicalTrials.gg
CompletedNCT05444556Updated Dec 12, 2025Results posted

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

A Phase 1 interventional study of Imlunestrant and Repaglinide in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical assessment
  • (BMI) within the range 18.0 to 35.0 kilograms per meter squared (kg/m²)
  • Female participants of non .

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to imlunestrant, related compounds or any components of the formulation, repaglinide, omeprazole, dextromethorphan, quinidine, rosuvastatin, or digoxin, as appropriate, or history of significant atopy.
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing
  • Use or intend to use any prescription medications/products within 14 days prior to first dose until completion of the follow-up visit, unless deemed acceptable by the investigator (or designee), including but not limited to medications that inhibit or induce cytochrome P450 (CYP) 2C8, CYP2C19, CYP2D6, P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Imlunestrant + Repaglinide (Cohort 1)

    Participants received: Day 1: A single oral dose of 0.5 mg repaglinide administered alone. Day 3: A single oral dose of 800 mg imlunestrant, followed approximately 2 hours later by 0.5 mg repaglinide, both administered orally.

    Drug: Imlunestrant · Drug: Repaglinide

  • Experimental
    mlunestrant + Omeprazole & Dextromethorphan (Cohort 2)

    Participants received: Day 1: A single oral dose of 20 mg omeprazole and 30 mg dextromethorphan, administered in the morning. Day 3: A single oral dose of 800 mg imlunestrant, followed immediately by 20 mg omeprazole and 30 mg dextromethorphan, all administered orally.

    Drug: Imlunestrant · Drug: Omeprazole · Drug: Dextromethorphan

  • Experimental
    Imlunestrant + Quinidine (Cohort 3)

    Participants received: Day 1: A single oral dose of 400 mg imlunestrant, administered in the morning. Days 15 to 17 and 19 to 24: Twice-daily oral doses of 200 mg quinidine, administered alone. Day 18: A single oral dose of 400 mg imlunestrant administered in combination with 200 mg quinidine (quinidine was dosed twice on this day as part of the regular regimen).

    Drug: Imlunestrant · Drug: Quinidine

  • Experimental
    Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)

    Participants received: Day 1: A single oral dose of 10 mg rosuvastatin and 0.25 mg digoxin, administered in the morning. Day 10: A single oral dose of 400 mg imlunestrant, administered in combination with 10 mg rosuvastatin and 0.25 mg digoxin, all administered orally.

    Drug: Imlunestrant · Drug: Rosuvastatin · Drug: Digoxin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1)

    PK: AUC\[0-∞\] of Repaglinide

    Time frame: Day 1 and Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose

  2. PK: Maximum Observed Concentration (Cmax) of Repaglinide (Cohort 1)

    PK: Cmax of Repaglinide

    Time frame: Day 1 and Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose

  3. PK: AUC[0-∞] of Omeprazole (Cohort 2)

    PK: AUC\[0-∞\] of Omeprazole

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  4. PK: Cmax of Omeprazole (Cohort 2)

    PK: Cmax of Omeprazole

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  5. PK: AUC[0-∞] of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)

    5-hydroxyomeprazole is a major metabolite of omeprazole.

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  6. PK: Cmax of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)

    5-hydroxyomeprazole is a major metabolite of omeprazole.

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  7. PK: AUC[0-∞] of Dextromethorphan (Cohort 2)

    PK: AUC\[0-∞\] of Dextromethorphan

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  8. PK: Cmax of Dextromethorphan (Cohort 2)

    PK: Cmax of Dextromethorphan

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  9. PK: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUC[0-tlast]) of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)

    Dextrorphan is a major metabolite of Dextromethorphan.

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  10. PK: Cmax of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)

    Dextrorphan is a major metabolite of Dextromethorphan.

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose

  11. PK: AUC[0-∞] of Imlunestrant (Cohort 3)

    PK: AUC\[0-∞\] of Imlunestrant

    Time frame: Day 1 and Day 18: Predose, 1, 2, 3, 4, 5, 6 ,8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post dose

  12. PK: Cmax of Imlunestrant (Cohort 3)

    PK: Cmax of Imlunestrant

    Time frame: Day 1 and Day 18: Predose, 1, 2, 3, 4, 5, 6 ,8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post dose

  13. PK: AUC[0-∞] of Rosuvastatin (Cohort 4)

    PK: AUC\[0-∞\] of Rosuvastatin

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose

  14. PK: Cmax of Rosuvastatin (Cohort 4)

    PK: Cmax of Rosuvastatin

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose

  15. PK: AUC[0-∞] of Digoxin (Cohort 4)

    PK: AUC\[0-∞\] of Digoxin

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose

  16. PK: Cmax of Digoxin (Cohort 4)

    PK: Cmax of Digoxin

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose

07

Results

Posted Dec 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneImlunestrant + Repaglinide (Cohort 1)Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2)Imlunestrant + Quinidine (Cohort 3)Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)
Started27273227
Received at least one dose of study drug27273227
Completed27273026
Not completed0021
Withdrew: Withdrawal by subject0021

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1)

PK: AUC\[0-∞\] of Repaglinide

Time frame:
Day 1 and Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1)
nanogram*hour per milliliter (ng*hr/mL)0.5 mg Repaglinide800 mg Imlunestrant + 0.5 mg Repaglinide
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1)13.0 ± 3113.6 ± 31
PrimaryPK: Maximum Observed Concentration (Cmax) of Repaglinide (Cohort 1)

PK: Cmax of Repaglinide

Time frame:
Day 1 and Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Repaglinide (Cohort 1)
nanogram per millilitre (ng/mL)0.5 mg Repaglinide800 mg Imlunestrant + 0.5 mg Repaglinide
PK: Maximum Observed Concentration (Cmax) of Repaglinide (Cohort 1)10.5 ± 389.84 ± 44
PrimaryPK: AUC[0-∞] of Omeprazole (Cohort 2)

PK: AUC\[0-∞\] of Omeprazole

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of Omeprazole (Cohort 2)
ng*hr/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: AUC[0-∞] of Omeprazole (Cohort 2)703 ± 77825 ± 74
PrimaryPK: Cmax of Omeprazole (Cohort 2)

PK: Cmax of Omeprazole

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Omeprazole (Cohort 2)
ng/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: Cmax of Omeprazole (Cohort 2)316 ± 73405 ± 57
PrimaryPK: AUC[0-∞] of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)

5-hydroxyomeprazole is a major metabolite of omeprazole.

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)
ng*hr/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: AUC[0-∞] of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)571 ± 26592 ± 19
PrimaryPK: Cmax of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)

5-hydroxyomeprazole is a major metabolite of omeprazole.

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)
ng/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: Cmax of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)200 ± 52230 ± 42
PrimaryPK: AUC[0-∞] of Dextromethorphan (Cohort 2)

PK: AUC\[0-∞\] of Dextromethorphan

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of Dextromethorphan (Cohort 2)
ng*hr/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: AUC[0-∞] of Dextromethorphan (Cohort 2)14.7 ± 12716.1 ± 111
PrimaryPK: Cmax of Dextromethorphan (Cohort 2)

PK: Cmax of Dextromethorphan

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Dextromethorphan (Cohort 2)
ng/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: Cmax of Dextromethorphan (Cohort 2)0.864 ± 1241.13 ± 124
PrimaryPK: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUC[0-tlast]) of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)

Dextrorphan is a major metabolite of Dextromethorphan.

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUC[0-tlast]) of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)
ng*hr/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUC[0-tlast]) of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)11.8 ± 6211.9 ± 75
PrimaryPK: Cmax of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)

Dextrorphan is a major metabolite of Dextromethorphan.

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)
ng/mL20 mg Omeprazole + 30 mg Dextromethorphan800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan
PK: Cmax of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)1.79 ± 501.97 ± 56
PrimaryPK: AUC[0-∞] of Imlunestrant (Cohort 3)

PK: AUC\[0-∞\] of Imlunestrant

Time frame:
Day 1 and Day 18: Predose, 1, 2, 3, 4, 5, 6 ,8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post dose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of Imlunestrant (Cohort 3)
ng*hr/mL400 mg Imlunestrant (Day 1)400 mg Imlunestrant + 200 mg Quinidine BID (Day 18)
PK: AUC[0-∞] of Imlunestrant (Cohort 3)1970 ± 661870 ± 87
PrimaryPK: Cmax of Imlunestrant (Cohort 3)

PK: Cmax of Imlunestrant

Time frame:
Day 1 and Day 18: Predose, 1, 2, 3, 4, 5, 6 ,8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post dose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Imlunestrant (Cohort 3)
ng/mL400 mg Imlunestrant (Day 1)400 mg Imlunestrant + 200 mg Quinidine BID (Day 18)
PK: Cmax of Imlunestrant (Cohort 3)61.0 ± 8254.3 ± 81
PrimaryPK: AUC[0-∞] of Rosuvastatin (Cohort 4)

PK: AUC\[0-∞\] of Rosuvastatin

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of Rosuvastatin (Cohort 4)
ng*hr/mL10 mg Rosuvastatin + 0.25 mg Digoxin400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin
PK: AUC[0-∞] of Rosuvastatin (Cohort 4)29.0 ± 4744.9 ± 51
PrimaryPK: Cmax of Rosuvastatin (Cohort 4)

PK: Cmax of Rosuvastatin

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Rosuvastatin (Cohort 4)
ng/mL10 mg Rosuvastatin + 0.25 mg Digoxin400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin
PK: Cmax of Rosuvastatin (Cohort 4)2.99 ± 535.08 ± 59
PrimaryPK: AUC[0-∞] of Digoxin (Cohort 4)

PK: AUC\[0-∞\] of Digoxin

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of Digoxin (Cohort 4)
ng*hr/mL10 mg Rosuvastatin + 0.25 mg Digoxin400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin
PK: AUC[0-∞] of Digoxin (Cohort 4)20.2 ± 2328.0 ± 19
PrimaryPK: Cmax of Digoxin (Cohort 4)

PK: Cmax of Digoxin

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Digoxin (Cohort 4)
ng/mL10 mg Rosuvastatin + 0.25 mg Digoxin400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin
PK: Cmax of Digoxin (Cohort 4)1.17 ± 391.88 ± 38

Adverse events

Collected over Cohort 1: up to 11 days, Cohort 2: up to 12 days, Cohort 3: up to 32 days, Cohort 4: up to 22 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5 mg Repaglinide: Cohort 10/27 (0%)0/27 (0%)2/27 (7.4%)
800 mg Imlunestrant + 0.5 mg Repaglinide: Cohort 10/27 (0%)0/27 (0%)0/27 (0%)
20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 20/27 (0%)0/27 (0%)3/27 (11.1%)
800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 20/27 (0%)0/27 (0%)3/27 (11.1%)
400 mg Imlunestrant (Day 1): Cohort 30/32 (0%)0/32 (0%)9/32 (28.1%)
200 mg Quinidine BID (Days 15 to 17): Cohort 30/32 (0%)0/32 (0%)3/32 (9.4%)
400 mg Imlunestrant + 200 mg Quinidine BID (Day 18): Cohort 30/31 (0%)0/31 (0%)0/31 (0%)
200 mg Quinidine BID (Days 19 to 24): Cohort 30/31 (0%)0/31 (0%)4/31 (12.9%)
10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 40/27 (0%)0/27 (0%)0/27 (0%)
400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 40/26 (0%)0/26 (0%)1/26 (3.8%)
Most frequent other events
Most frequent other events
Event0.5 mg Repaglinide: Cohort 1800 mg Imlunestrant + 0.5 mg Repaglinide: Cohort 120 mg Omeprazole + 30 mg Dextromethorphan: Cohort 2800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 2400 mg Imlunestrant (Day 1): Cohort 3200 mg Quinidine BID (Days 15 to 17): Cohort 3400 mg Imlunestrant + 200 mg Quinidine BID (Day 18): Cohort 3200 mg Quinidine BID (Days 19 to 24): Cohort 310 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 4400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 4
HeadacheNervous system disorders1/270/273/271/274/321/320/312/310/271/26
ConstipationGastrointestinal disorders0/270/270/271/273/320/320/310/310/270/26
DiarrhoeaGastrointestinal disorders0/270/270/272/270/321/320/312/310/270/26
NauseaGastrointestinal disorders1/270/270/270/270/322/320/310/310/270/26
Back painMusculoskeletal and connective tissue disorders0/270/270/270/272/320/320/310/310/270/26
MyalgiaMusculoskeletal and connective tissue disorders0/270/270/270/272/320/320/310/310/270/26

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Imlunestrant + Repaglinide (Cohort 1)Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2)Imlunestrant + Quinidine (Cohort 3)Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)Total
Mean53.3 ± 8.252.6 ± 8.255.9 ± 6.354.1 ± 7.154.1 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Imlunestrant + Repaglinide (Cohort 1)Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2)Imlunestrant + Quinidine (Cohort 3)Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)Total
Female27273227113
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Imlunestrant + Repaglinide (Cohort 1)Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2)Imlunestrant + Quinidine (Cohort 3)Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)Total
Hispanic or Latino2219231478
Not Hispanic or Latino5891335
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Imlunestrant + Repaglinide (Cohort 1)Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2)Imlunestrant + Quinidine (Cohort 3)Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)Total
American Indian or Alaska Native00000
Asian11002
Native Hawaiian or Other Pacific Islander00000
Black or African American354719
White2321271990
More than one race00112
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Imlunestrant + Repaglinide (Cohort 1)Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2)Imlunestrant + Quinidine (Cohort 3)Imlunestrant + Rosuvastatin & Digoxin (Cohort 4)Total
United States27273227113
08

Study locations

3 sites
  • Altasciences Clinical Los Angeles, Inc
    Cypress, California 90630, United States
  • Qps-Mra, Llc
    South Miami, Florida 33143-4875, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Nov 2022, 3 months.

Results were first posted in Dec 2025, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 6, 2022
StartActual
Jul 7, 2022
Primary completionActual
Nov 2, 2022
CompletionActual
Nov 2, 2022
Results first posted
Dec 12, 2025
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05444556
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Jul 7, 2022
Primary completion
Nov 2, 2022
Completion
Nov 2, 2022
Results posted
Dec 12, 2025
Last update
Dec 12, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion